Roche turns to a Har­vard up­start out of George Church’s lab to con­struct AAV 2.0 mod­el vec­tors — a key part of build­ing the gene ther­a­py pipeline

For a gene ther­a­py tech up­start that launched out of stealth mode just 5 months ago with big goals and not a tremen­dous amount of launch mon­ey, Dyno Ther­a­peu­tics has quick­ly moved it­self in­to a front­line of­fen­sive in R&D — work­ing in league with some of the mar­quee de­vel­op­ers in the field.

Build­ing on al­liances with No­var­tis and Sarep­ta, the glob­al Roche/Genen­tech group has now stepped in with the lat­est dis­cov­ery deal, will­ing to wa­ger up to $1.8 bil­lion that the spin­out from George Church’s lab at Har­vard has what it takes to de­liv­er on AAV 2.0. There’s an up­front, but the part­ners are keep­ing that part mum. But while most ear­ly-stage deals are heav­i­ly back end­ed, there’s a big enough num­ber here to make a dif­fer­ence on the bank bal­ance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER